Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2024 | $220.00 → $255.00 | Neutral → Buy | BofA Securities |
| 5/8/2024 | $265.00 → $225.00 | Buy → Neutral | BofA Securities |
| 4/19/2024 | $285.00 | Outperform | RBC Capital Mkts |
| 3/19/2024 | $250.00 | Overweight | Morgan Stanley |
| 2/6/2024 | $278.00 | Overweight | KeyBanc Capital Markets |
| 1/19/2024 | $245.00 | Buy | Jefferies |
| 1/2/2024 | $210.00 | Buy → Hold | Stifel |
| 12/13/2023 | $245.00 → $187.00 | Overweight → Equal Weight | Wells Fargo |
BofA Securities upgraded Inspire Medical Systems from Neutral to Buy and set a new price target of $255.00 from $220.00 previously
BofA Securities downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $225.00 from $265.00 previously
RBC Capital Mkts initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $285.00
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2024. Recent Business Highlights Generated revenue of $203.2 million in the third quarter of 2024, a 33% increase over the same quarter last yearAchieved gross margin of 84.1% in the third quarter of 2024Generated $14.3 million in operating income and earnings per share of $0.60 in the third quarter of 2024Generated cash flow from operations of
MINNEAPOLIS, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the third quarter 2024 after the close of trading on Monday, November 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the followi
MINNEAPOLIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2024. Recent Business Highlights Generated revenue of $195.9 million in the second quarter of 2024, a 30% increase over the same quarter last yearAchieved gross margin of 84.8% in the second quarter of 2024Generated $5.1 million in operating income and earnings per share of $0.32 in the second quarter of 2024Activated 81 new U.S. centers in
MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. Webcast replays of the presentations will be available for two weeks following the presentations in the Event Archive section of Inspire's Investor website at https://
MINNEAPOLIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Inspire is scheduled to present at 7:30 a.m. Eastern Time. The presentation will be accessible via a live webcast here. Webcast replays of the presentations will be available for two weeks following the presentations in the Event Archive section of Inspire's Investor website at https://investors.i
MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire," or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it entered into an accelerated share repurchase ("ASR") transaction under an agreement with Goldman Sachs & Co. LLC, to repurchase an aggregate of $75.0 million of shares of the Company's common stock, par value $0.001 per share. The ASR transaction is being completed pursuant to a previously announced $150.0 million share repurchase program authorized by the Company's Board of Directors.
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
10-Q - Inspire Medical Systems, Inc. (0001609550) (Filer)
8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)
"Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, with uninterrupted CE mark approval since 2010," said Tim Herbert, Chairman and President of Inspire. "The Inspire team has worked diligently with our notified body in Europe to complete the review process, which included obtaining temporary approval through derogation authorization to continue to deliver Inspire product in several countries." "In 2017 the European Parliament enacted a new regulatory framework (i.e., EU MDR 2017/745) for the certification of medical devices in the EU. As a result, the entire medical device industry must repeat the process for both design and quali
Ratings for Inspire Medical Systems (NYSE:INSP) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 2 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $220.33, a high estimate of $285.00, and a low estimate of $170.00. Highlighting a 9.
For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today the addition of Melissa J. Mann as Chief People Officer, effective July 22, 2024. "We are very excited to welcome Melissa to the Inspire team," said Tim Herbert, Chairman and CEO of Inspire. "In this role, Melissa will be able to leverage her vast experience in human capital management as we continue to grow and scale our organization. Melissa is replacing Steven L. Jandrich, Vice President, Human Resources, who
MINNEAPOLIS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the retirement of Marilyn Carlson Nelson as Chair of its Board of Directors and the appointment of Chief Executive Officer Timothy P. Herbert to the additional role of Board Chair, to be effective at the conclusion of the Company's Annual Meeting of Stockholders scheduled to occur on May 2, 2024. "Marilyn has had a profound impact on our business and our employees through her many years on the board," said